ライフサイエンスコーパス: pacemaker implantation

1 ke, valvular or congenital heart disease, or pacemaker implantation.

2 c benefits similar to those of ablation with pacemaker implantation.

3 dog died of cardiopulmonary arrest prior to pacemaker implantation.

4 ted CHB has an excellent prognosis following pacemaker implantation.

5 planted using techniques similar to standard pacemaker implantation.

6 in 11 patients, who then required permanent pacemaker implantation.

7 mptoms decreased in 118 patients (75%) after pacemaker implantation.

8 lable therapy for SSS consists of electronic pacemaker implantation.

9 major bleeding, sinus node dysfunction, and pacemaker implantation.

10 pileptic drug changes, epilepsy surgery, and pacemaker implantation.

11 tentially life-threatening complications and pacemaker implantation.

12 essive atrioventricular (AV) block requiring pacemaker implantation.

13 inus node (pacemaker) disease and electronic pacemaker implantation.

14 inus syndrome (SSS), a common indication for pacemaker implantation.

15 acing sites may be considered at the time of pacemaker implantation.

16 ly 2 months and was severe enough to lead to pacemaker implantation.

17 nd chronic (6 months to 4 years) phases post-pacemaker implantation.

18 , group A had a significantly higher rate of pacemaker implantation.

19 associated with a higher short-term rate of pacemaker implantation.

20 No patient required pacemaker implantation.

21 Twelve underwent pacemaker implantation.

22 f residual aortic regurgitation and need for pacemaker implantation.

23 rwent pressure-volume studies at the time of pacemaker implantation.

24 of rapid ventricular rate during AF without pacemaker implantation.

25 ith longer follow-up, and some patients need pacemaker implantation.

26 (AF) is irreversible and requires permanent pacemaker implantation.

27 oventricular delay for 1 week after elective pacemaker implantation.

28 fter atrioventricular (AV) node ablation and pacemaker implantation.

29 r interest is the low incidence of permanent pacemaker implantations.

30 There were no deaths, strokes, or permanent pacemaker implantations.

31 2% (95% CI: 2.1% to 4.8%); and new permanent pacemaker implantation, 13.9% (95% CI: 10.6% to 18.9%).

32 ever, BAV was associated with lower rates of pacemaker implantation (2.9% versus 8.0%; P<0.001) and b

33 similar patients who underwent ablation and pacemaker implantation ($28 302+/-2023, P<.001).

34 within 12 +/- 10 months and met criteria for pacemaker implantation; 77 of 89 patients were randomly

35 the risk of a complete heart block requiring pacemaker implantation (8.1% versus 1.7%; P=0.005).

36 (adjusted OR, 1.23; 95% CI, 1.02-1.50), and pacemaker implantation (adjusted OR, 1.21; 95% CI, 1.06-

37 No patient required pacemaker implantation after a mean follow-up time of 32

38 isk of conduction disturbances and permanent pacemaker implantation after TAVR, with prior right bund

39 e a pacemaker, whereas 23 patients underwent pacemaker implantation after the echocardiogram.

40 In patients who needed permanent pacemaker implantation after the procedure (n=35), 31.4%

41 ntly observed in patients after dual-chamber pacemaker implantation and can be associated with advers

42 ties for establishing central venous access, pacemaker implantation and cardiothoracic surgery.

43 ent (but had higher prevalence of stroke and pacemaker implantation) and had worse health-related qua

44 olute risk increases were 1.04% (AF), 0.53% (pacemaker implantation), and 2.05% (all-cause mortality)

45 r AF, 1.22 (95% CI, 1.14-1.30; P < .001) for pacemaker implantation, and 1.08 (95% CI, 1.02-1.13; P =

46 481 participants developed AF, 124 required pacemaker implantation, and 1739 died.

47 F, 59 (95% CI, 40-87) vs 6 (95% CI, 5-7) for pacemaker implantation, and 334 (95% CI, 260-428) vs 129

48 is associated with atrial fibrillation (AF), pacemaker implantation, and all-cause mortality.

49 al is associated with increased risks of AF, pacemaker implantation, and all-cause mortality.

50 istory of heart failure or valvular disease, pacemaker implantation, and uninterpretable electrocardi

51 The incidences of stroke, bleeding, and pacemaker implantation (but not acute kidney injury) als

52 h a significant higher rate of new permanent pacemaker implantation compared with the Edwards prosthe

53 nced an increased risk of new-onset HF after pacemaker implantation compared with those without AVB.

54 Follow-up after dual-chamber pacemaker implantation demonstrates that nearly 30% of p

55 Patients who ultimately met criteria for pacemaker implantation did not differ from those who did

56 ard lowering the rate of reinterventions and pacemaker implantations following ASA because, in this a

57 After epicardial atrial gene transfer and pacemaker implantation for burst atrial pacing, animals

58 ence and time course for developing HF after pacemaker implantation for cAVB.

59 After NSRT, the incidence of pacemaker implantation for complete heart block was high

60 ventricular pacing in patients who underwent pacemaker implantation for isolated congenital atriovent

61 In cases of pacemaker implantation for non-life-threatening situatio

62 equency catheter ablation of the AV node and pacemaker implantation for rate control of medically ref

63 identified patients undergoing dual-chamber pacemaker implantation from 2008 to 2014.

64 plications in all patients undergoing ICD or pacemaker implantation from August 2004 to August 2007.

65 are more complicated and costly than simple pacemaker implantation, future directions will be for mu

66 .36-3.12; P < .001), 3-fold adjusted risk of pacemaker implantation (HR, 2.89; 95% CI, 1.83-4.57; P <

67 lar junction ablation was required in 3% and pacemaker implantation in 14%.

68 ular arrhythmias in 3%, tamponade in 3%, and pacemaker implantation in 20%.

69 egree atrioventricular block in 1, permanent pacemaker implantation in 3) and excessively prolonged Q

70 usion in 17.5%, clinical stroke in 1.8%, and pacemaker implantation in 3.0%.

71 ated with (1) total death, sudden death, and pacemaker implantation in a model, including CTG expansi

72 erm survival free of new heart failure after pacemaker implantation in isolated congenital atrioventr

73 e QRSd was obtained from 12-lead ECGs before pacemaker implantation in MOST, a 2010-patient, 6-year,

74 leads led our unit to undertake transvenous pacemaker implantation in neonates and infants from 1987

75 Data are scarce on outcomes of pacemaker implantation in nonagenarians (age>/=90 years)

76 equency catheter ablation of the AV node and pacemaker implantation in patients with atrial fibrillat

77 ars of age (n=115 683) who underwent initial pacemaker implantation in the 2004 to 2008 Healthcare Co

78 lees (73+/-10 years) undergoing dual chamber pacemaker implantation in the Protect-Pace study.

79 ident AF in patients undergoing dual chamber pacemaker implantation, independent of left atrial volum

80 cedures such as right heart catheterization, pacemaker implantation, invasive electrophysiology testi

81 loping economies, there are patients in whom pacemaker implantation is delayed because they cannot af

82 However, only pacemaker implantation is predictive of long-term outcom

83 Epicardial pacemaker implantation is the favored approach in childr

84 had more conduction abnormalities requiring pacemaker implantation, larger improvement in effective

85 In patients who ultimately underwent pacemaker implantation LV function did not differ from t

86 Cardiac tamponade, permanent pacemaker implantation, major vascular damage, and moder

87 ndle-branch block and the need for permanent pacemaker implantation may have a significant detrimenta

88 fe-threatening bleeding of 5%, and post-TAVI pacemaker implantation of 12%.

89 . transfemoral approach), need for permanent pacemaker implantation (p = 0.02), and post-implant peri

90 Quality of life improved significantly after pacemaker implantation (P<0.001), but there were no diff

91 orrhage requiring transfusion, and permanent pacemaker implantation (P<0.001).

92 11.6 to 273.9) along with need for permanent pacemaker implantation post-procedure (pooled OR: 2.6; 9

93 eft bundle branch block (LBBB) and permanent pacemaker implantation (PPI) after transcatheter aortic

94 ta exist on the clinical impact of permanent pacemaker implantation (PPI) after transcatheter aortic

95 onduction disturbances or previous permanent pacemaker implantation (PPI) who underwent TAVI with a b

96 ated cardiac lesions, history of arrhythmia, pacemaker implantation, prior surgery of any type, and p

97 In contrast, AVN ablation with pacemaker implantation produces retrograde activation (s

98 complications (2.2% versus 6.5%), as well as pacemaker implantation rate (12.0% versus 15.2%), were s

99 No differences were observed in pacemaker implantation rate (9.8% versus 8.8%, P=0.94) a

100 Annual permanent pacemaker implantation rates and patient demographics we

101 ference in major aortic injury and permanent pacemaker implantation rates between groups.

102 sfemoral; P = 0.79), bleeding complications, pacemaker implantation rates, or moderate aortic insuffi

103 d atrioventricular block requiring permanent pacemaker implantation, remain the most common complicat

104 time, whereas rates of cardiac tamponade and pacemaker implantation significantly increased.

105 After pacemaker implantation, these seven patients reported a

106 brillation was lower with TAVI, but risk for pacemaker implantation, vascular complications, and para

107 e frequency of AF during the 3 months before pacemaker implantation was analyzed.

108 Pacemaker implantation was associated with the use of a

109 Permanent pacemaker implantation was required in 3 out of 35 patie

110 Rate of pacemaker implantation was significantly higher with the

111 Need for permanent pacemaker implantation was significantly higher with the

112 Heart block requiring permanent pacemaker implantation was the most common adverse outco

113 A higher rate of new permanent pacemaker implantations was observed in patients receivi

114 Baseline QRSd from 12-lead ECGs before pacemaker implantation were analyzed in the Mode Selecti

115 node dysfunction scheduled for dual-chamber pacemaker implantation were prospectively enrolled.

116 Patients indicated to pacemaker implantation were prospectively enrolled.

117 h heparin after implantable defibrillator or pacemaker implantation were randomized to receive intrav

118 Patients underwent pacemaker implantation, were randomized to DDDR with the

119 Two patients have required pacemaker implantation, whereas the rest are in sinus rh

120 rther excluded those who underwent permanent pacemaker implantation within 48 hours after the procedu

121 After pacemaker implantation, younger patients (</=55 years of